Full Transcript Introduction to Dr. Bill Lawrence 0:00 Ladies and gentlemen, welcome back to the Bioregulator and Peptide Summit. 0:03 Today we have an amazing guest. 0:06 We have the man who's been working in bio regulator 0:12 research really for the last. 0:13 What is it, ten years now doctor Bill Lawrence. 0:16 Yes, yes. 0:17 So doctor Bill Lawrence is a longevity researcher and bio gerontology scientist 0:22 with a focus on translating complex research on bio regulators, biological 0:27 aging, and epigenetic regulation 0:28 into frameworks that are accessible to Western clinicians and researchers. 0:33 Enhancing understanding and collaboration. 0:36 This man's not about the hype, my friends. 0:37 This man's about what did the numbers say? 0:40 And it is honestly quite apart from the sparkling personality and amazing 0:45 dancing skills. 0:46 One of the many reasons why I truly love this guy. 0:50 Now, Doctor Lawrence is closely associated with the scientific legacy of Vladimir, 0:55 whose laboratory and clinical studies investigated organ specific peptide 0:59 bio regulators that regulate gene expression, tissue repair, and age related 1:03 functional decline. 1:03 So, in case you missed any of the other episodes 1:06 where we explain this, now, you know what they do. 1:08 Doctor Lawrence's role has centered on mechanistic interpretation, 1:11 clinical synthesis, and biomarker anchored evaluation, particularly using 1:15 epigenetic aging measures, telomere biology and systems levels, biomarkers. 1:20 He's presented and discussed peptide biotech 1:22 extensively in physician facing and scientific forums, emphasizing 1:26 measure based based outcomes, translational biology, and cautious 1:30 differentiation among hypotheses, clinical observations, and published evidence. 1:34 His current work explores how peptide based interventions may interact 1:38 with repair, signaling, stem cell niches, and age associated transcriptional drift. 1:44 Doctor Lawrence originally trained as an attorney, 1:47 then as a scientist, and has recently completed 1:50 an exhaustive investigation into genetic longevity claims. 1:54 So that's a topic we're going to explore in the podcast. 1:57 But today we are going to give you guys a 2:01 we're going to run a discussion really about the work that you do. 2:04 So welcome, Doctor Lawrence. 2:06 It is a pleasure to have you back. 2:08 It's my pleasure to be here. 2:11 So for listeners who are new to your work, can you give us a very, very brief 2:15 origin story about what 2:16 drew you to the bio regulator peptide specifically, 2:19 and what made you decide to run your own clinical trials 2:22 rather than just study the Russian data or, 2:27 you know, or even just use it for yourself, 2:29 take the money and run, as it were. 2:30 And for people who want more details 2:32 on your real origin story, we're going to direct them to the podcast. 2:34 But just let's let people know what what really drew you to this area of study? 2:40 Okay. 2:40 The short version is that the men 2:43 in my family line all die early 2:47 without going into all the detail. 2:49 It's just a terrible record. 2:51 They all die in their 50s and early 60s, including grandparents. 2:56 My own father had his first heart attack at 57, died at 64, 3:02 and I was doing a lot of entrepreneurial things at that time. 3:06 I had kind of left law, and I was building medical buildings and shopping centers 3:10 and just a whole bunch of stuff worse creative tango in my life. 3:14 I'm a semi hermit and entrepreneurial ship, 3:18 and being a hermit sort of don't fit well together. 3:22 They don't go very well together. 3:24 No, no. 3:25 So anyway, with my father's death, I decided on going down the wrong track. 3:29 I'm making. 3:30 I'm making lots and lots of money and my kids will appreciate it, 3:33 but I won't, you know, based on the family history. 3:36 And I probably was about 43 or 4 at that point. 3:40 I've only got maybe 20 more years. 3:43 I'd better change the direction, so I did. 3:46 I went back to school and got the PhD in nutritional science, 3:49 started doing research for what I would call integrative 3:52 or holistic physicians and clinics who wanted to have an objective, 3:57 alternative understanding 3:59 of some of the clinical studies that were being published 4:01 by the pharmaceutical industry and so forth. 4:03 I did that for a while, and then I got very interested 4:07 in my longevity and longevity generally. 4:10 So I started searching. 4:12 It was Google Translator that allowed me to be able to see clinical studies 4:15 from all over the world. 4:16 And I kept running into these clinical studies
Origin Story and Family Longevity Motivation 4:19 that Professor Kevin Sin was involved with out of Russia. 4:23 And the results that they were getting using something called 4:27 peptide bio regulators at that point were remarkable. 4:30 I mean, just a significant 4:32 mortality reduction, which would translate into longevity. 4:36 And so basically, I went to Russia at that point. 4:41 Yeah. I mean, yeah. 4:42 What else would you eat? 4:43 The man what else would you do exactly. 4:46 You go meet the man himself. 4:47 And yeah, I think from the first episode you basically I've, 4:51 I've sometimes said, you know, 4:53 when you threw himself at his feet and said, you must work with me, 4:55 you've got to help me figure this out. 4:57 And probably it was more elegant than that. 4:59 But he couldn't resist. 5:00 You invest and and agreed to work with you? 5:03 Yeah. 5:04 I think what happened was he was so stunned 5:06 because there's very little still true, very little communication 5:11 between Russia, as I'll say in the US in terms of science world and so forth. 5:15 And he I think he was just so stunned that 5:20 and I wouldn't call myself a scientist at that point. 5:22 You know, I had the PhD, 5:24 but that an American would be interested in anything that the Russians are doing. 5:28 So he just basically took office and I in and we became close 5:33 and I basically studied under him, soaked up everything I could possibly get 5:38 from him over, I guess about an 8 to 9 year period of time. 5:43 Yeah, yeah. 5:44 What an opportunity. So fortunate. 5:47 Yeah. What a beautiful thing. 5:48 So you worked with him and the Saint Petersburg Institute of Bio 5:52 Regulation and Gerontology. 5:54 Really? 5:54 I dug up since 2015, in some way, shape or form. 5:58 So how is so what has that collaboration looked like over the years 6:01 and how has it shaped the research you've been gone on to do in the States? 6:06 Yeah. Good question. 6:08 Professor Cameron was was primarily interested in developing new peptides. 6:13 That was his passion. 6:15 And but his focus was really on 6:18 using the peptides for organ regeneration, 6:21 which translated into people were having medical problems. 6:24 And if they were organ related, he was developing peptides that would actually 6:29 at the cellular level of tissue level and so regenerate those organs. 6:33 And in many cases that would, you know, be very helpful 6:37 for at least improving if not resolving, you know, the medical conditions. 6:42 And so like the peptides for the kidney were wonderful in terms of people who 6:48 had been diagnosed with kidney disease, even some people who were, you know, 6:54 at late stage and the kidney peptides 6:57 and a couple others that he would use would reverse that situation. 7:00 So that that was his mission. 7:02 I guess I would say I came along with this idea that I want to live a long time. 7:07 I want to make it past my ancestors and so forth. 7:11 So I proposed to him, you know, you've got these wonderful peptides, 7:14 you've got this data in terms of mortality reduction studies and so forth. 7:19 And I said, but what do you think about longevity? 7:22 And he just wasn't terribly interested in that. 7:25 He wanted to reduce mortality. 7:27 And of course there's this overlap, you know when you talk about 7:30 and mortality reduction. 7:31 So again, because he was really focused on organ regeneration and helping people 7:36 medically, he basically said, you know, if you want to do something 7:40 more specific to longevity, let's put together a clinical study. 7:44 So he helped me, supported me, taught me, 7:47 you know, pretty much everything that I gleamed at that point. 7:51 And we decided we would do a clinical study in America using American 7:56 labs, using American participants and an American administrator myself. 8:01 And that's what we launched in about 8:02 2000, actually, we started talking about in 2015. 8:06 We launched it in 2017. 8:09 And so my job was to administer, 8:12 you know, the clinical study for longevity. 8:16 Yeah. No it's fine. 8:17 And, you know, the the interesting thing when we say longevity versus mortality, 8:22 when he did his initial studies with the with the elderly people that he did 8:27 that were, you know, 8:28 kind of the ones that when you 8:29 throw up the slides on a, on a board, people really pay attention to this. 8:32 And at the time I remember reading, look, he wasn't going to see the reason 8:36 why researchers don't do longevity trials, if you will, on humans, 8:40 is because they just take to flip and long like we live too long. 8:44 And so when he's so he kind of flipped it on his head and said, well, 8:47 can we prevent people or can we, can we make it 8:50 so that people don't die as soon? 8:52 And it was it's an easier line to draw in the sand than it is to see 8:56 how long are these people going to live. 8:58 So, you know, at the end of the day, the end result is the same. 9:01 If we can help people live longer, healthier lives, whether we say 9:05 that we've reduced mortality or improved longevity, 9:07 the endpoint is the same more, more or less. 9:12 Yeah. 9:12 When we get into the the whole pipe program, 9:16 I define longevity as being different than mortality reduction. 9:21 I have a very specific criteria 9:25 we need to be able to with proxies, telomeres and epigenetics. 9:29 We need to be able to add 20 years 9:32 or more to their lifespan 9:37 in order to consider a legitimate longevity intervention. 9:41 And okay, we'll talk more about that in that slide. 9:44 Yeah. Okay. Good. 9:45 Because I have a question about that. Cool. 9:46 All right. 9:47 So let's talk about you a little bit more 9:49 because you're just the fascinating guy in the room here. 9:52 So you're now you've you've achieved the first objective. 9:56 You've outlived any man in your, 10:00 you know, in as long as you've looked back in your genealogical tree, 10:04 let's say your tree, you're in your late 70s, 10:08 but your telomere age is reportedly equivalent to that of a 23 year old. 10:13 So take take us on a little trip through your own personal data. 10:18 What does your biological but what is your logical profile look like? 10:22 But also really importantly, what about your health? 10:25 How does it look like today to compared to when you started? 10:28 And how much of it do you think has to do with that change in lifestyle 10:31 that you talked about because you went from being kind of, 10:35 we'll call you a reluctant entrepreneur fighting against your own nature 10:39 to do work that you felt was important, but that really wasn't feeding you to.
Telomere Testing and Personal Health Data 10:45 Now you're living a life that is very different, 10:47 but at the same time, I think you're you're burning the candle 10:50 definitely heavily at one end, 10:52 if not both ends, just because of the work that you do. 10:54 So maybe walk us through your your data a little bit just to 10:58 just to repeat the question, 10:59 how does your biological and health profile 11:01 look like today compared to when you first started? 11:03 Okay, the interesting thing is we have actually data. 11:07 It isn't just an impression, but we have the data. Yes. 11:10 So I did my first telomere test in 2012 actually. 11:15 Yeah. 11:16 And I knew just a little bit about telomeres. 11:20 I knew they had something to do with cell replication. 11:22 And so because in my PhD program, we touched on it, my first test 11:27 with Specter Cell trying to guess now I was 11:30 I think 64, 65, I can't remember. 11:33 And I was five years older telomere wise. 11:36 In other words, my telomeres were equivalent to a male 11:39 five years older than my chronological age. 11:41 And this is before I even heard the term peptide bio regulators. 11:45 And so then two years later was when I was 11:48 basically in Russia, had met professor 11:51 and started on a peptide bio regulator program for general health, 11:56 but specifically to see what I could do with those telomeres. 11:59 And I have a slide that we've used in you and I've used in the past 12:04 that tracks the telomere process over many, many years. 12:08 And so it was about a year and a half after I started on the peptides, 12:14 particularly the pineal gland peptides that I first 12:18 got to a point where my telomere age was younger than my chronological age. 12:24 So he had dropped by about six years at that point. 12:28 And then I would retest every year and a half or two years later, and in 12:33 various segments it would be ten years, the last ten years less, and so forth. 12:39 In terms of the telomere situation, until I think my last test 12:44 was about a year or so ago, and there were two tests that came in 12:48 over a period of four years that showed my telomere equivalent to a 23 year old. 12:53 So nice, huge extension of telomeres and what we know. 12:56 And I talk about it, you know, we've talked about it in some prior 13:00 podcasts is telomeres have a really wide 13:05 ranging impact on people's health, because telomeres are 13:09 what allows cell replication to occur in in a perfect manner. 13:14 That is, you know, 13:15 we have several replication going on all the time in ourselves. 13:18 And as we get older, as these telomeres on the end of our end caps deteriorate, 13:23 that replication becomes negatively impacted to some degree. 13:27 And so to be able to then reverse that and add telomerase, 13:31 we call it through the enzyme to the to the cells basically not perfectly, 13:37 but certainly has a major impact on rejuvenating my entire body, 13:41 my all my systems and so forth, because it's all the trillions of cells 13:45 that are being employed. 13:47 So I was not the healthiest, but not the unhealthiest 13:51 young attorney when I first started, before I went to Russia and so forth. 13:54 You know, the long hours and then doing all neural stuff, 13:58 I would get the common cold and strep throat and so forth. 14:02 And I was overweight probably by 10 or 15 pounds, 14:05 and not just due to the peptides, but realizing that the peptides are wonderful. 14:11 And we'll talk a little bit more about them. 14:13 But I had to clean up my whole act, had to leave the weight, had to start, 14:18 you know, being a young attorney and you you would know this, you know, 14:21 with your son being at a law firm, your workweek is 70 to 80 hours a week. 14:28 You don't have time to do anything 14:30 other than eat, sleep and go and go back to the law firm. 14:33 So yeah, I was not in great shape anyway. 14:36 So then with the addition of the telomere extension since that time, I would say 14:41 since since at least 2015, I haven't had a cold, haven't had the flu. 14:48 Yeah that's amazing. 14:49 Healthy is going to be. 14:51 Do you have an opinion on the one of the fears 14:55 that is articulated quite often by people who are just learning about by regulators 15:00 is they worry that by 15:04 supporting telomeres, we could somehow end up supporting cancer cells. 15:09 Do you have an opinion on that? 15:10 I do, yes, because there's enough literature. 15:13 It's sends, you know, discussed it and so forth. 15:16 There's an association with cancer and extended telomeres. 15:21 And another telomerase gets that enzyme gets activated when people have cancer. 15:25 But it's an association situation. 15:28 The cancer does are the telomeres do not cause the cancer. 15:32 But what a person is diagnosed with cancer. 15:35 There's this rapid replication of cells. 15:38 And the telomerase enzyme gets activated at that point. 15:41 But it doesn't call cancer. 15:44 So then would we say that for someone who is dealing with cancer 15:48 that they know about that maybe the the pineal gland bio regulator 15:52 would be something to stay away from until they've kind of gotten to a place 15:57 where they get the kind of green light from the medical team. 16:00 Yeah. 16:01 As to be very cautious about it. 16:04 And careful we don't take anybody into the clinical study. 16:07 If they've had a history of cancer during the prior five years, 16:10 or certainly if they have a cancer diagnosis presently, 16:13 we don't think it would be a problem, but we don't want to take the chance. 16:17 Yeah. Great. Thank you. 16:19 It's just it's one of those things that just keeps coming up. 16:21 And, you know, there's there's a couple of of fears in the peptide world. 16:25 And that's one of the ones that gets touted around. 16:27 So thank you for answering that okay. 16:30 So many people conflate peptide bio regulators with synthetic 16:35 with not just synthetic but longer chain peptides like BPC 157 or TB 500. 16:41 Can you clearly distinguish for people what peptide bio regulators 16:45 actually are, why they're different, and why that distinction really matters? 16:49 When you're doing work in the longevity 16:51 space, like you or the work that you're doing in the longevity space. 16:54 Sure. 16:55 I call them synthetic or therapeutic peptides. 16:57 They've been around, you know, 16:59 they're the hot item, of course, here in the United States these days. 17:02 They've been around for a long, long time. 17:04 I mean, 17:06 and people 17:07 don't realize that, for instance, insulin is a peptide. 17:11 Yeah. Yeah. 17:11 I mean, long history. 17:13 Anyway, you see the two of them as being complementary. 17:15 And I'll define that in a moment. 17:17 The synthetic peptides are wonderful for short 17:21 term acute issues like wound healing. 17:24 You know, BPC 157 ligament healing and so forth, muscle healing, etc.. 17:28 The TB 500, the mosses, you know, all all of those are wonderful. 17:33 I use started using them about six months ago. 17:36 Their commentary in that they are focused on a specific, you know, issue. 17:42 So for instance, there are, you know, peptides for mitochondrial regeneration. 17:47 And so they're great to have that in your tool bag. 17:50 The peptide and bio regulators 17:52 are completely different in that they don't fix things in the short term. 17:56 It takes a long time for a peptide bio regulator to to become effective. 18:01 And what the reason is that the bio regulators are going in 18:05 at the cellular level and regenerating through cell signaling, 18:10 regenerating tissues, which has the benefit 18:14 of regenerating entire organs and eventually the whole system 18:18 and the human body system. 18:19 So it's a long process. 18:21 And the key is the I, I would say that the synthetic peptides, 18:26 I don't want to call them medicine, but insulin of course, is 18:29 a medicine is a medicine, but they're in the field 18:33 of fixing a problem that a person has medically okay. 18:37 Health. Yeah. Like right now. 18:38 And the other hand, the peptide bio regulators are a long term process. 18:43 We know from the clinical studies that did you know he had some studies over 18:49 six years long, nine years long, 12 years long with the old person study. 18:53 We know from the work I've been doing the last ten years or so that it takes 18:57 3 or 4 years in most cases to achieve the goals 19:02 that we set, Telenor wise and epigenetics, and we'll get into that. 19:06 But even just to improve significantly, like probably the one of the quickest 19:12 bio regulators that we see with benefits is the thyroid. 19:18 I'm not a doctor and so I have to be careful. 19:21 But we have, I don't know, 80 or 90 doctors in our clinical study. 19:25 I think there's over 150 people now and they use them for their patients. 19:30 And of course, study. 19:31 And the feedback that I get from labs that the doctors sometimes send me 19:35 or talk to me about the last me to prepare 19:39 a thyroid regeneration protocol.
Cancer Risk, Safety, and Peptide Distinctions 19:43 And we see generally the labs improving in about six months, 19:47 which is really a fast turnaround for peptide bioreactors, because 19:51 what we're doing is we're regenerating, you know, at a cellular level. 19:55 But yeah, it's a long process and it's doing something different. 19:59 It's remodeling the system by, you know, fixing the plumbing and fixing, 20:04 you know, the HVAC and fixing, you know, the windows and, 20:08 you know, paving the repaving the driveway and all that stuff. 20:12 Yeah, yeah. All those renos we love to do. 20:15 Where's the synthetics are more like, you know, putting a new coat of paint on it. 20:19 You know, it'll look nice and it is, you know, good and so forth. 20:23 But yeah. 20:24 Yeah. 20:24 So when you talked about the, the, 20:27 the thyroid numbers improving over over six months, 20:31 and one thing I'd like to highlight for the audience is quite often 20:35 the thyroid by regulator is being used adjacent to all the other tools 20:41 that the medical doctor is going to be applying to the problem. 20:44 Right. 20:45 So whether they're changing their diet to get rid of certain anti nutrients 20:49 or they're reducing inflammation 20:51 in the body or they're addressing lifestyle like I, 20:55 I've seen this myself in my membership community, 20:57 and I do think it's important for people to, to know that we're not just 21:01 popping a couple of capsules a day and calling it a day. 21:05 We're doing all that other work around it. 21:07 But it's it's the it's the combination of the support of actions 21:12 that you're taking both from a lifestyle and even, you know, 21:17 maybe you have a selenium deficiency or iodine, whatever the case may be. 21:20 So addressing deficiencies and then adding the bio regulator on top 21:26 that's doing that infrastructure upgrade, if you will, that 21:29 allows for the for these numbers to shift in a meaningful way. 21:33 But you said over six after six months, are you 21:36 are you able to tell us with these doctors, are they using the thyroid 21:41 bio regulator, 21:41 let's say for the full six months, or are they pulsing it over the six months? 21:45 I'm sure it varies from case to case, but can you again 21:49 help people to understand, 21:50 is this just a one and done 30 day protocol, or maybe do they have 21:54 is it beneficial to kind of repeat shorter cycles within that period of time? 21:59 Can you help people to get a little insight on that? 22:02 Certainly 22:04 it depends on a degree of safety were it issues or kidney issues and so forth. 22:09 The general program is you've used the word pulsing 22:14 cabin and determined it was very important to do this cycling of this cabin 22:18 or a pulsing thing, because he did not want to have the body 22:23 become reliant on the constant in stream or intake of these peptide 22:27 bio regulators, because if that was the case, 22:30 then the body's natural organ functionality and so forth 22:34 would decline over a period of time. 22:36 Be dependent on this constant input of peptide, 22:40 you know, which are signal signaling molecules. 22:43 And so his program basically different than mine in 22:46 that his program was two capsules a day of a particular peptide 22:51 for ten days of the month and then off for 20 days and maybe 22:56 recycle, maybe do nothing for a couple of months 22:59 and then started again, very conservative kind of thing. 23:03 And he was getting very good results with that. 23:06 My approach has been a little, well, let's take the person. 23:09 No, that's got a serious kidney thyroid situation. 23:13 My approach is a little more aggressive. 23:15 I would take someone like I shouldn't say I, I would recommend to the doctor okay. 23:20 Because I interact individually with okay. 23:23 I would say to the doctor, let's put them on a pretty aggressive 23:27 dose, two capsules a day for 30 days, maybe in 60 days, 23:31 and then drop it down to two capsules for 20 days for a couple of months, 23:36 and then drop it to the traditional two capsules a day for ten days. 23:39 I do not think it's necessary to have large gaps, like a cabin set would. 23:44 Maybe use a thyroid peptide three times in the course of the year. 23:49 Yeah, I'm much more aggressive, and the reason for that 23:52 is that I can't hurt them. 23:55 Yeah. 23:55 The their natural derive from food. 23:58 They're just a little amino acid strings and so forth. 24:01 And so there are no adverse events. 24:03 There's no side effects whatsoever. 24:06 So my approach that I talked with the doctors about is 24:10 since we can't hurt this person overdosing, 24:13 and we can only get benefits from this, at least in the short term, 24:17 because eventually we need to get on to a cycling. 24:19 Let's be aggressive. 24:21 So that's basically what we do when we set up the programs. 24:25 But we also for the clinical studies, we actually do 24:28 some of that rotation that cabin in has in his history. 24:32 Because, for instance, I might have a person 24:35 on, say, 4 or 5 different peptides for the first three months. 24:38 And unless they have a medical problem, we're going to be on the ten 24:42 days, two caps a day for those people. 24:44 But then the next three month period of time, we're going to 24:47 shuffle three other different because there's 21 of them available. 24:51 We'll use three other peptides for that period of time. 24:54 And then the following three months, a whole, you know, a 24:58 different group of them. 24:59 So in many ways we're still on Cabin Suns cycling program. 25:04 But the difference is that when he was doing 25:07 those studies, he only had a couple of peptides 25:09 because he hadn't developed many of the others, 25:11 the pineal and the thymus, peptides or the old people studies. 25:15 I have 21 of them that I can use. 25:18 Yeah, I have a whole toolkit. Yeah. Really exciting. 25:21 And so what we do with a person that comes into the clinical study 25:24 and these are doctors mostly, is we set up a 12 month 25:28 protocol for them rotating through all of the peptides. 25:31 And the result of 25:32 that is on the whole we get we use three everybody every three months. 25:37 Let's say we use three boxes or we use the thymus peptide 25:41 three times during the year, which is what I was doing. 25:46 Yeah. 25:47 Yeah. No that's fantastic. 25:48 Thank you. So you answered one of my other questions. 25:50 Basically, you know, I was going to ask why all 21. 25:53 And that is essentially you're up. 25:55 I mean why would you only upgrade part of the system 25:57 if you're going to upgrade your factory, you may as well clean all the machinery, 26:01 upgrade all the components so that you get 26:05 efficient production of all the things that you need. 26:08 So I have another question for you. 26:09 In the old people's study, Kevin Sin only used the peptides 26:15 that he did have for two years and then followed these people for 26:19 in the one study 12 years, and then in the next study six years. 26:23 And even then he only administered them a couple of times a year. 26:26 In those two years, when you're working with people now 26:30 and you're doing this whole system overhaul, how long, how many, 26:34 how long do you think people need to be cycling through the peptides? 26:38 And then should they take a break for a couple of years and then come back, 26:41 or are we watching labs and the, 26:45 you know, any testing results, which we'll talk about later, I guess, 26:48 and then revisiting different bio regulators 26:51 when we start to see signs that function is declining in any way. 26:56 The way that I approach it is that we set goals for people that, you know, 27:03 as you said in the early part 27:04 of this, longevity standards are difficult because they're long. 27:08 Okay. Yeah. Yeah. 27:09 So we have to do it with proxies and the proxies that we use. 27:13 And there are half a dozen good proxies out there. 27:15 But the two that we cabins and I agreed upon was the telomeres and epigenetics, 27:21 because telomere testing at that time was readily available. 27:24 Epigenetics came along pretty much about to 20 2020 27:31 I guess is when it's around there. 27:33 Yeah. Yeah. 27:34 So what we do is we set goals. 27:36 So let's say a person who is 60 years old, I suggest you 27:42 then that we can lengthen their telomeres and get them equivalent to a 35 year old. 27:47 So that becomes the goal. 27:48 And we actually set those goals on the documentation on the protocols. 27:52 And with the epigenetics we'll get into how we measure it. 27:55 But the epigenetics is is a risk factor. 27:59 In other words, if you're older epigenetic than your chronological age 28:02 by a certain amount, you have an increased all cause mortality risk. 28:07 And for that, the goal becomes to get people down 28:11 about 4 or 5 years below their chronological age, 28:14 because at that point they drop into a 35 to 50% 28:17 reduced all cause mortality risk compared to their same age peer. 28:21 So those are the goals. 28:22 And so to answer your question, I'm being a little bit long winded. 28:26 What we have discovered is it takes about a minimum of three years 28:30 to get people close to or at those goals, sometimes just as on the individual. 28:36 And by the way, 28:36 we don't tell people or ask people to change anything in their life. 28:40 Yes, yes, that is a really important. 28:42 I have no idea what the diet is, but basically because most of these people 28:46 are autistic or holistic integrative physicians, their diet is good. 28:52 You know, they're doing that. 28:53 Work is being done for sure. Yeah. 28:55 So takes us 3 or 4 years and we get to that point most of the time. 28:59 I would say over 90% of the time we get to really close to those goals 29:04 or achieve those goals. 29:05 Then cabins and and I, being a little naive at the time, thought we would say 29:10 goodbye. 29:11 We did it, you know, you're done. Yeah. We're done. 29:14 Come back and see us in five years. 29:16 The problem? 29:17 Nobody leaves. 29:19 We get there and they say, yeah, but I don't want to stop.
Pulsing Protocols and Long-Term Peptide Cycling 29:24 So we had to create a maintenance program, 29:26 and we have probably 40 of the 150 on a maintenance program 29:30 where we send them two different peptides a month for ten days. 29:34 You know, and at this point, I think 29:37 in all these years, I think we've only had one person just kind of drop out. 29:42 And he said, he'll come back to us in five years, which is fine. 29:46 Yeah. Yeah. 29:47 So you're kind of like doing a little tweaking, tweak mints along 29:50 the way, just making sure that things stay primed. 29:53 It makes total sense to me. All right. 29:55 So one of the one of the I feel like one of the things, 29:59 one of the thoughts you've advanced here, that wasn't always the language 30:02 that was used before 30:03 is you described this as a DNA repair system restoration rather than anti-aging. 30:09 And this is not just semantics. Can you. 30:11 Can you explain that a little bit? 30:13 What does restoring the DNA repair system really mean? 30:16 And why is it more accurate than saying you're reversing aging? 30:20 Yeah, it's actually nothing. 30:22 The two are totally different. 30:25 Yeah. What we have the DNA repair systems. 30:27 I am just always overwhelmed at the complexity and the wonderment 30:31 of human bodies and how we operate and so forth. 30:36 Within ourselves, cells replicate all the time. 30:39 Okay. 30:40 It's called the Hayflick limit is the total number that they can. 30:43 And by the way, cabins and published a clinical study 30:46 where he was able to extend the Hayflick 30:49 limit, which is been the Holy grail for 50, 60 years. 30:52 He was able to extend the Hayflick limit, the number of replications 30:56 by 40%. 30:59 Yeah. 30:59 Anyway, so what happens at the cell level is that cells are, 31:03 you know, replicating and so forth. 31:05 And in that process, the course that they're replicating and they split, 31:09 you know, into what they call daughter daughter cells and so forth. 31:12 They split. 31:13 And the idea is that these new cells are a perfect 31:17 reproduction of the cells that was there before. 31:20 Okay. 31:20 And what occurs, though, is that there are what we call 31:24 assaults, mutations, whatever you want to call them. 31:28 When that cells replicating it doesn't always replicate 100% perfectly. 31:34 There are I exposure, 31:37 stress, bad food, toxic environment. 31:40 There's just a whole long list of things that can interfere with that replication. 31:45 So think of you've got a sort of an assembly line 31:48 here of cells being replicated 99.9% of the time. 31:51 That cell is going to replicate just fine. 31:54 It becomes a new, perfect functioning cell. 31:56 Sometimes it doesn't happen. 31:58 In fact, in this DNA repair system, it is like being on an assembly line. 32:03 And at one point there's what's called in scientific literature, checkpoint. 32:08 There is a a part of this process, 32:12 this DNA repair system that looks at the in a sense. 32:16 I'm oversimplifying, but it looks at this new cell for a moment. 32:19 A nanosecond says there's something wrong with that and kick it out. 32:22 And there are options. 32:24 They don't just trash it. 32:25 They say, send it over here, the repair shop. 32:28 Okay, guys will take a look at it and decide if it can be repaired 32:32 or if it's just too, too much gone, in which case we'll destroy it. 32:36 So that's the checkpoint that goes on in the body, which is incredible. 32:39 That happens. 32:41 The DNA repair system is the repair shop, the repair maintenance department 32:47 that goes on in our system, and it works perfectly. 32:51 When we're young, over a period of time, it becomes 32:55 less perfectionist and less functional. 32:58 And as we then see aging accelerated organ 33:03 damage, because, you know, if you're like a foundation, the bricks in a foundation, 33:08 if some of them are cracking and so forth, that has an impact on the structure. 33:11 And so what happens is that the peptides 33:15 can come in and actually fix the DNA repair system. 33:19 It could come into that maintenance department and say, yeah, 33:22 you guys need to go get some training, and we need some new tools over here. 33:26 And, you know, obviously simplifying it, but the pair system can be repaired. 33:31 And Kevin San published several studies where he talks about 33:35 he doesn't use repair, but that's what he was alluding to. 33:38 So the peptides can go in and fix the DNA repair system itself. 33:44 Numbers tune it back up to what it was like when we were born. 33:48 Yeah, that is amazing kind of thing, because then cell 33:51 replication is going to continue to go at a high quality level 33:55 because the maintenance department has been fixed, you might say. 33:59 And most humans, it doesn't get fixed. 34:01 It just deteriorates until we're old. 34:04 Yeah. 34:05 No, that's why I don't I don't talk about in terms of anti-aging. 34:09 I talk about in terms of cellular integrity when cell replicated. 34:16 Well, and I also think to avoid the word 34:18 anti-aging respects the philosophy of Professor Who. 34:22 And he talks about extending the lifespan and health span 34:26 of organisms to their natural to their natural endpoint. 34:30 So he wasn't talking about people living to 200 or 180 years old. 34:34 He was talking about, you know, if human lifespan is, 34:39 let's pin it at, let's say, peg it at 120 years. 34:42 That would be the maximum lifespan that we could expect. 34:46 Then he he's saying, 34:47 you know, most people are leaving, let's say to 80 or into their 80s. 34:50 What can we do to extend that, give them that extra, 34:55 you know, 20 to 40 years, let's say, but do it in a way that they actually live 34:59 a life worth living 35:00 as opposed to just keeping them alive, which we all know medicine can do. 35:05 Medicine can keep people alive way past a point where maybe we'd 35:09 want to be alive just because of what our quality of life might look like. 35:13 The goal here really is that, you know, Bill, invest, continue 35:17 ballroom dancing well into their 80s and 90s and beyond. 35:21 And the rest of us just keep doing the things we enjoy and contributing 35:24 and enjoying our time on this earth 35:28 well into those decades. 35:31 Yeah, actually, Kevin talks about the humans should be able to survive 35:35 fairly and be healthy at 110 to 120. 35:39 He talks about and some of his articles on self-worth and 35:42 but a big part of that there's two components going on. 35:45 You've got to fix the DNA. 35:47 You got to fix the maintenance department. 35:49 Okay. 35:50 Yeah, the maintenance department, if it is deteriorating over time, 35:54 that means the cells are going to be vulnerable and so forth. 35:58 At the same time, you use the peptide biograph 36:01 not not only to redo the maintenance department, 36:04 but you use them to fix the organs where cells didn't replicate as well. 36:09 When there's been some external damage, you know, a wound or whatever 36:13 that you know. 36:14 So you use the peptides for that as well. 36:17 The combination of those two even ruling on. 36:20 I'm not saying eliminate, but even ruling out considerations 36:23 of how healthy your lifestyle is and so forth, which really supports 36:26 that cabins and strongly believes 120. 36:30 I expect this and I expect to be alive of 120. 36:33 And as we've talked about in prior podcast, the Crossing the Bridge concept. 36:40 Yeah, yeah, I love that concept. 36:42 Yeah. 36:42 And we'll just mention it quickly that there's things on the drawing board. 36:46 In fact, I talk a lot about this in the longevity Hope hype PowerPoints. 36:51 There are things on the drawing board that within 510 years are going to. 36:57 I mean, dementia probably will disappear. 36:59 Cardio disease, diabetes and all those things 37:03 will probably disappear, particularly when you add AI into the picture. 37:07 You got to stay as healthy as it can be in order to get over this, 37:12 say next ten years and at that point is 140 feasible? 37:16 Maybe. Yeah. 37:18 Yeah, maybe. 37:19 I mean, with AI, who knows what can happen? 37:22 Yeah. 37:23 Well, and it's about regenerative medicine and where it's going. 37:26 Right. 37:26 So now we're going to be, 37:28 you know, if we can refresh, renew regenerate joints that are wearing down. 37:32 And to your point, 37:34 beating those chronic diseases that are the things that ultimately take us down. 37:38 But I think where the bio regulators come in 37:41 is if they can keep that immune system balanced and functioning, 37:45 that puts us in a much better position as well. 37:47 Like it's all of these things, you know, those would be that that immune 37:50 bio regulator that sometimes I don't know that it gets its day, 37:54 it gets enough attention because everybody's 37:56 so focused on the pineal gland. 37:57 But it's like, yeah, pineal gland is great, 37:59 but if your immune system goes wonky, it doesn't really matter. 38:02 So when the protocols we create by Neil Gland and the thymus peptides 38:08 are used more consistently throughout the year. 38:11 You know, I talked about those cycles every three months. 38:13 Almost always the pineal and the thymus peptides are built into 38:18 I would say probably all four of those three month cycles. 38:22 It's that important. Yeah. 38:24 Yeah. No. 38:25 When I was I, when I did my Year by Regulators program with my people, I think 38:30 everybody was getting it once a quarter and especially over a certain age. 38:34 Right. 38:34 Like once you're north of I don't know if we want to 38:36 I mean, we're I don't know where you peg your number. 38:38 For me, it's definitely over 60, but even over 50, if somebody's living 38:42 a very stressful, busy, 38:45 crazy life, every quarter is not inappropriate. 38:48 Absolutely. Yeah, absolutely. Yeah. Okay. 38:51 So we we talked a lot about the telomere study where, you know, 38:56 I think you mentioned earlier that over 90% of the people that you worked 39:00 with achieved those goals of telomere lengthening. 39:03 Is that right? 39:04 Or did we not say that or am I making that up? 39:07 Yeah. No, you're not making it up. But it's not exactly 39:10 the attorney brain kicking in and the science. 39:13 Yeah, I know 39:13 I listen, I'm always really careful with you because I, 39:16 the attorney brain is a very precise brain. 39:18 It's kind of like the engineer brain. 39:19 Only difference what we have been able
DNA Repair, Cellular Integrity, and Aging 39:23 to achieve, percentage wise is pretty much 39:26 I would I'd have to go back and statistically. 39:30 But I would say 95% or more, 95 to 98% of the people 39:35 experience telomerase activation and telomere lengthening. 39:39 Okay. 39:40 Very, very few do not recognize something. 39:45 Now, we talked about goals in terms of what percentage reached the goals okay. 39:50 Never sat down and and figured it out as a percentage. 39:54 It is certainly a majority of the people. 39:56 It's probably somewhere around 75 to 85% of the people hit the goals. 40:01 So that 65 year old person I mentioned earlier, we set the telomere 40:05 goal at 35, 75, 80% of the people hit that or get real close to it. 40:11 And then there's a small percentage that don't, 40:14 but they have show improvement. 40:15 I don't think there's we've never had a person I want to make sure this is true. 40:20 We've never had a person whose telomeres go the wrong way, go the wrong age. 40:26 Yeah, yeah, yeah. 40:27 Because I know that we've had some that just didn't get much. 40:30 And yeah, we talk about this in some other podcast, what we believe 40:35 based on science cabinets, sense work and others is if people are under 40:39 huge amounts of stress, it does a little number on the telomeres. 40:44 Yeah, yeah, yeah. So folks this is your cue. 40:47 If you're not learning, if you're not accessing tools to manage that stress, 40:53 that is probably one of the key features that accelerates aging. 40:56 I mean, obviously there's others, 40:58 but that's the one that's probably the most under our control. 41:03 Not that you're going to reduce stress, but that you're going to manage. 41:05 You're going to help your body to manage it better. 41:07 And that's those are that's a very important distinction to make. 41:10 So okay, we're we're of course we're running long because it's us. 41:13 And because this topic is so fascinating. 41:16 Before we run completely out of time, I wanted to talk a little bit 41:19 about the epigenetic methylation study, 41:23 because that is a very other that's 41:25 another very key component of the work that you do with people. 41:29 And in general, you talked about earlier that you were showing 41:34 a five year reduction in epigenetic age, or that was the goal 41:37 that you were establishing for most people. 41:39 And this really correlates. Yeah. Well, okay. 41:42 About a five year reduction. 41:45 What we need is 41:46 them to be five years below their chronological age, 41:50 because some people come in and we are older baseline tests, 41:55 they're like ten years older epigenetic right than their chronological age. 41:59 So yeah right. 42:01 So it's five years younger than the chronological age. 42:03 So for some people they're starting at baseline. 42:05 For other people they're starting way behind the eight ball. 42:08 So it's going to take a little longer to get there. 42:09 So how are you measuring epigenetic age these days. 42:12 Are you using the Horvath clock that I need and pace. 42:15 Is there other like how are you interpreting that mortality correlation 42:19 okay. 42:20 We're using harvest clock for the 42:23 mortality reduction statistics and the goals that we he said 42:28 he's the one that determined for instance, if you're seven years old or epigenetic 42:33 you have about an 80% all cause mortality risk. 42:37 Okay, this is 42:39 and when I say horrible, Horvitz and 65 other scientists that work with him 42:43 at UCLA and other institutions came up with this data. 42:46 On the other hand, if you're five years younger than your chronological, 42:49 you have about a 45 to 50% reduced 42:53 all cause mortality risk compared to your peer. 42:56 So that's the that's the data that we use to create the protocol for them. 43:02 And so we are able to test the testing 43:05 originally in 20 2020. 43:08 I guess it would just give us an age to diagnostic, you know. 43:13 Yeah. Ryan. 43:14 And and and so forth were the pioneers in that area for commercially 43:19 I mean epigenetics going on and institutions. 43:22 Oh yeah. So they made it commercially. 43:25 And so they were able to give us just an epigenetic age. 43:28 Okay. And we then factored that in. 43:31 Then about a year later they broke it down. 43:34 And they could give us the epigenetic age of the immune system 43:38 separately from the overall, which was really wonderful thing. 43:42 And oh yeah, there's a couple years later they were able to break it down 43:46 further and I think they had 13. 43:49 I think they called the Symphony Age. 43:52 They do. 43:52 Yeah. It goes by system. It's it's actually fascinating. 43:55 Yes it is. 43:56 They have I think 13 organs and systems that they can give us 44:00 an epigenetic age for. 44:01 And of course what's wonderful about that is that when I'm looking at that data 44:07 and I'm designing a protocol for the people 44:10 we see, the one, the systems and organs that are accelerated. 44:14 So we build into the peptide program peptides to address that. 44:19 Now since time we've added another layout called Generation Lab 44:23 and they're doing something very similar. 44:26 That's just a bit different technology that they use. 44:29 And so I oftentimes do both tests for people. 44:32 They have actually 19 systems that they are able to report on. 44:37 Now all of that is very separate from the what we call the pace of aging, 44:42 that you would know pace of aging is able to tell us 44:46 how many years of chronologically we age one year every 12 months. 44:51 Okay. 44:51 And what they're able to do with the done in pace of aging is 44:55 they can figure out, or are we in a situation 44:59 where the person has accelerated aging, their their aging, say, 45:04 5% faster than their chronological aging or slower? 45:09 A wonderful thing. 45:10 In fact, I actually look at the rate of aging as the most important thing. 45:14 Yeah. 45:14 And so the goal there is to be able to slow people's 45:20 pace of aging, which sounds sci fi, but it's real. 45:23 I mean, it's fascinating. Yeah. 45:25 This stuff came out of Harvard and New York, you know, and so forth. 45:28 The institutions. 45:29 So it's it's real. 45:30 And that's the first thing I look at. 45:32 And so the goal that we set is I want people to have at least 45:36 a 7% slower pace of aging than their chronological age. 45:40 And we achieve that all the time. 45:43 Mine right now is 21% slower 45:47 than my chronological -70 0.79. 45:52 Yeah, yeah, I'm I'm not far. 45:55 I think I'm around there as well. 45:57 Wonderful. Congratulations. 45:58 We definitely want to be we want to be burning 46:01 through the clock less slower than the clock is going moving. 46:04 And I consider I mean the others are very important. 46:07 The telomeres are important, you know, and the grief of the systems. 46:11 But to be able to slow our biological aging, 46:15 you know, take the foot off the accelerator and kind of coast 46:18 along at 20% slower than, you know, the chronological. 46:22 Unbelievable. That's a real focus for me. 46:26 So yeah. 46:27 Anyway, we use we use all of that. 46:30 Perfect I love that. 46:31 So, you know, I'm going to wrap this up and we're going to leave 46:34 a lot of questions on the table. 46:36 But but for folks we have a bunch of there are a number of podcasts 46:40 that Doctor Lawrence and I have recorded in the past. 46:43 We're going to be recording another one for the podcast down the road, 46:46 so I think we've covered some good ground here. 46:49 But one of the things I wanted to address is that, you know, 46:51 we have a lot of people listening to this podcast, this summit, 46:54 some of them will be physicians who I'm sure you'll hear from, and 46:59 some of them will be the general public, some of whom you may also hear from. 47:02 Or they'll come to me asking to get in touch with you, 47:05 because that's generally how we run this. 47:07 But do you think that this the protocols that we've outlined here, 47:11 which are not very specific, but let's say somebody 47:13 listening is a layperson, they're like, oh my God, I'm jumping in. 47:16 I'm doing this. 47:17 Do you think that people can do this on their own? 47:20 Or do you feel that it requires medical supervision? 47:23 Are there any risks or contraindications you feel people should be aware of 47:27 if they're going to, 47:28 if they're going to DIY this themselves, other than a little hit to the pocketbook. 47:32 And these peptides are not all that expensive really, 47:35 other than those, you know, a bit of a financial investment.
Epigenetic Age, Pace of Aging, and Study Results 47:40 There are no adverse. 47:41 You can't hurt yourself because again, the basis for these 47:45 are animal source, either calves or pigs and so forth. 47:50 They've been around since 1970s with Kevin. 47:54 Yeah, they've been around for a long time. 47:57 Several million people have been. 47:59 And one thing I want to add before I finish this is, 48:03 yeah, a common criticism of the Russian peptides 48:07 is that no one outside of Russia has duplicated the studies. 48:10 That's not true at all. 48:12 Yeah. 48:13 And we're going to talk about it later in the other, 48:15 Kevin said worked with other countries health departments, 48:19 you might say, or academies and so forth, including the National Institute 48:23 of Health in America. He. Yeah. 48:26 You know, working with them, the Belgium, Italy, Germany, etc.. 48:31 And the other criticism is that there aren't any published 48:34 clinical studies, you know, outside of Russia. 48:37 That also is incorrect in the program we're going to do later, 48:41 I list the number of international publications, 48:44 and the most recent one on telomeres is last year out of the Netherlands. 48:50 Yeah, yeah. Anyway, back to your question. 48:53 I think a person could because there's no downside. 48:57 Okay. 48:58 I think a person could use the probably for, for say a male, there's 49:02 probably about 20 of the peptides for same for for women because you know, 49:08 the metals aren't going to use the ovaries and so forth or the testing. 49:10 Yeah. 49:11 You could just take those and rotate through the as I said earlier, 49:15 the foundational ones are the penal gland and the thymus. 49:18 Those should be every probably at least every three months those. 49:21 But take and lay out a protocol yourself 49:24 so your budget cats can absorb, say four different peptides a month. 49:29 Just scatter those out, you know, get the muscle peptide, the kidney peptide, 49:33 the brain peptide, the vision peptide, and create a protocol for yourself. 49:37 And then just by the peptides I think you have a source. 49:42 Yeah, yeah, yeah. 49:43 As a matter of fact, I think I believe profound health. 49:46 As of next week, we'll be shipping out of the US instead of out of the UK. 49:50 So I have a we'll be hearing from them in the summit too. 49:53 It's very exciting 49:55 next week from fill out of Florida. 49:57 Yeah. There you go there. 49:59 You can't hurt yourself. 50:01 And so just create your own program. 50:03 Get Ahold of Naftali and she'll help you buy them and just start using it. 50:08 I mean, there's new bouncer. 50:09 Yeah, yeah, unless unless I'm just going to go back to the beginning. 50:13 If you have active cancer or a history of cancer in the last few years 50:17 there, you're going to need to exert caution. 50:19 And I would definitely work with a professional at that point 50:22 just because just because we don't want to take any chances. 50:26 All right. 50:27 One more. 50:28 There are the natural bio regulators. 50:30 And then there are synthetic forms of bio. 50:34 Do you? 50:35 Maybe we can help people understand the differences between the two. 50:38 And I know that originally you really mostly use the natural. 50:42 And since then you've now incorporated some of the synthetic bio 50:46 regulators like the Apatow on spray or whatever case may be. 50:50 Can you just help orient 50:51 people in this area a little bit before we shut this down? 50:55 Okay. 50:55 I would recommend that people stay 50:58 with the natural peptides to start with the first year or so. 51:02 Okay. 51:03 The spread with, you know, the 20 plus or 21 plus, 51:06 it will take care of all the major organs and systems if you have 51:11 the synthetic ones are helpful because they're faster acting. 51:15 Okay. 51:15 If you can identify, I think there's less than a dozen. 51:19 I think at this point of the synthetics floating around, depending on, you know, 51:23 if it'll on in the spray and so forth. 51:26 You know, 51:27 if you have a particular health issue, I would consider using the synthetics. 51:32 I carry a small inventory because the doctors like them. 51:35 We don't we don't use them in the clinical study 51:38 because our whole study was set up on the others, on the natural. 51:42 Yeah. 51:43 So okay, now there's a lot of noise in the longevity space. 51:47 Right now we're going to touch. 51:48 There's going to there's another podcast coming you guys. 51:51 So you're going to have to listen to that to get the full answer to this question. 51:54 But you know this in the longevity space right now we talk about synthetics. 51:57 We talk about GLP. 51:58 We talk about NAD precursors. 52:01 Yamanaka factor reprogram. 52:02 Where do you 52:03 where would you put the bio regulator peptides in the hierarchy of interventions 52:07 that you'd recommend. 52:08 And do you see them working synergistically 52:10 with some of these other protocols when they're appropriate? 52:14 That's interesting. 52:15 You raise that question because in the PowerPoint that we're going to do later, 52:20 it's in there 52:22 is what I do 52:23 do is I go through the the hope kinds 52:27 of supplements and nutraceuticals and stuff that's out there. 52:31 I go through the hype idea because there's a lot of hype out there. 52:34 And then I go to a selection of what I call science. 52:39 There are eight different interventions 52:43 that have longevity benefits to meet my criteria. 52:48 My criteria is different than a lot of the talking people 52:53 on these shows talk about. 52:54 And I talk yeah, they're the peptide. 52:56 Bio regulators are the most powerful longevity 53:01 in terms of my criteria, most longevity, 53:04 most potent longevity item on the planet. 53:07 At the moment with human studies, there are experimental 53:12 things that we have high hopes for, like NAD and all these other things. 53:16 I think that the GLP are going to be really, really a game changer, 53:21 but we don't. 53:22 The dividing line for me as a scientist is and I talk about this in this thing, 53:26 most of what you hear on YouTube about this wonderful thing 53:29 for longevity and so forth, and we have science to support it. 53:33 The science is animal based. Okay, 53:37 okay. 53:37 Because only 5%, maybe 7% at best. 53:42 Do animal study results transfer to human being? 53:46 Yeah, 5%. 53:48 So you can't rely on yeah there's there's studies and so forth and so forth. 53:52 When you narrow it down non 53:55 it can't be animal studies and it has to hit this criteria. 53:59 There's only about eight things that really create longevity. 54:04 And the peptide bio regulators at the moment are the leading. 54:07 And it's 54:08 not just because I'm involved with them I'm involved with them because I went. 54:12 But that's why you're involved with running water. 54:14 So I could be around, you know, play with my, my great grandkids. 54:18 So that's right. Yeah. That's right. 54:21 Okay. All right. 54:22 I'm just deciding how we're going to close this off. 54:25 All right. 54:25 If there's one thing you wish that the conventional medical establishment 54:29 understood about bio regulator peptides that it currently does not, 54:32 what would it be? 54:33 It would be for them, the conventional medical world to take the blinders off, 54:38 take take away the pharmaceutical funding and all that stuff that goes on. 54:42 And if they were to simply look at the science and say, here's 54:48 what's available and what's helpful for my patients and so forth. 54:53 They would incorporate the peptide bio regulators into their practices, 54:57 especially given the fact that almost all pharmaceutical drugs
DIY Use, Natural vs Synthetic Peptides, and Closing Thoughts 55:00 have some degree of adverse side effects. 55:04 They would also 55:05 race the synthetic peptides because on the whole, they're very safe. 55:09 We don't have a lot of data, but on the whole but they do wonderful things. 55:13 They would open up their practice, use synthetics, use peptide bioreactors, use 55:18 their traditional medical things and so forth, because they would be 55:22 the service that they would be offering. 55:24 And I'm starting to see this. 55:25 You know, there are doctors, 55:27 MDS that are in our program, of course, that have opened up there. 55:31 You know, 55:31 they've added 55:32 the peptides to their program, they've added the synthetics and so forth. 55:35 Can you imagine going in and seeing a doctor who has all those tools available? 55:40 Yeah, yeah, that's what I say I love that. 55:44 What's the thing that surprised you the most 55:46 after nearly a decade of running this study? 55:48 What's the thing that you didn't anticipate seeing when you started? 55:51 I think it probably would be what I said earlier. 55:54 I thought I'd be with these people for 3 or 4 years. 55:57 Right. They won't go home. 56:00 I mean, I have a list of fortunately, I got Lori to to respond, but I've got 56:04 like 20 emails this morning from people that have been with me for 8 or 10 years. 56:10 Yeah. 56:11 That's amazing, I love it. 56:12 It's it's the sign of, of doing great work. 56:15 So if somebody wanted to and, you know, I'll put it out there. 56:18 If anybody does want to think about explore working with Doctor Lawrence 56:23 and now his new superhuman assistant, Lori, you can reach out to me directly, 56:27 and there's a process in place, and I can help you to navigate that. 56:31 In the meantime, I think I'm going to now let you go. 56:33 We've now gone 50% over the time we were supposed to go. 56:36 So I'm going to thank you so much, Doctor Lawrence, for your time. 56:41 As always. You're so generous with it and your wisdom. 56:44 Is there anything else you'd like to share with the audience before we say goodbye? 56:47 Yeah. There is. 56:49 Every morning when I wake up, I recite to myself 56:52 five things that I'm grateful for, and 56:57 being alive is right at the top there. 57:00 That's my wonderful wife. 57:02 Is there? 57:02 The work that I do, it sets for me the tone for the day. 57:07 Because some days when I think is that I'm not excited about doing 57:11 it gives me a chance to kind of put it in the right perspective. 57:17 That's what I finish with. 57:18 Be grateful that we just woke up this morning. 57:21 Beautiful, beautiful. Thank you. Okay. 57:24 Thank you so much as always a pleasure. 57:26 It is my pleasure.
Comments